170 related articles for article (PubMed ID: 11502857)
61. Molecular and cellular basis of depigmentation in vitiligo patients.
Delmas V; Larue L
Exp Dermatol; 2019 Jun; 28(6):662-666. PubMed ID: 30536790
[TBL] [Abstract][Full Text] [Related]
62. Possible roles of B lymphocyte activating factor of the tumour necrosis factor family in vitiligo autoimmunity.
Lin X; Tian H; Xianmin M
Med Hypotheses; 2011 Mar; 76(3):339-42. PubMed ID: 21075543
[TBL] [Abstract][Full Text] [Related]
63. Autoimmune vitiligo does not require the ongoing priming of naive CD8 T cells for disease progression or associated protection against melanoma.
Byrne KT; Zhang P; Steinberg SM; Turk MJ
J Immunol; 2014 Feb; 192(4):1433-9. PubMed ID: 24403535
[TBL] [Abstract][Full Text] [Related]
64. Autoimmune aspects of vitiligo.
Kemp EH; Waterman EA; Weetman AP
Autoimmunity; 2001; 34(1):65-77. PubMed ID: 11681494
[TBL] [Abstract][Full Text] [Related]
65. Increased sensitivity of melanocytes to oxidative stress and abnormal expression of tyrosinase-related protein in vitiligo.
Jimbow K; Chen H; Park JS; Thomas PD
Br J Dermatol; 2001 Jan; 144(1):55-65. PubMed ID: 11167683
[TBL] [Abstract][Full Text] [Related]
66. Emerging role of immune cell network in autoimmune skin disorders: An update on pemphigus, vitiligo and psoriasis.
Das D; Akhtar S; Kurra S; Gupta S; Sharma A
Cytokine Growth Factor Rev; 2019 Feb; 45():35-44. PubMed ID: 30773437
[TBL] [Abstract][Full Text] [Related]
67. Autoimmune vitiligo is associated with gain-of-function by a transcriptional regulator that elevates expression of HLA-A*02:01 in vivo.
Hayashi M; Jin Y; Yorgov D; Santorico SA; Hagman J; Ferrara TM; Jones KL; Cavalli G; Dinarello CA; Spritz RA
Proc Natl Acad Sci U S A; 2016 Feb; 113(5):1357-62. PubMed ID: 26787886
[TBL] [Abstract][Full Text] [Related]
68. Current remedies for vitiligo.
Abu Tahir M; Pramod K; Ansari SH; Ali J
Autoimmun Rev; 2010 May; 9(7):516-20. PubMed ID: 20149899
[TBL] [Abstract][Full Text] [Related]
69. Maintenance of immune hyporesponsiveness to melanosomal proteins by DHICA-mediated antioxidation: Possible implications for autoimmune vitiligo.
Liu XM; Zhou Q; Xu SZ; Wakamatsu K; Lei TC
Free Radic Biol Med; 2011 May; 50(9):1177-85. PubMed ID: 21256957
[TBL] [Abstract][Full Text] [Related]
70. Patients affected by vitiligo and autoimmune diseases do not show antibodies interfering with the activity of the melanocortin 1 receptor.
Agretti P; De Marco G; Sansone D; Betterle C; Coco G; Dimida A; Ferrarini E; Pinchera A; Vitti P; Tonacchera M
J Endocrinol Invest; 2010 Dec; 33(11):784-8. PubMed ID: 20332705
[TBL] [Abstract][Full Text] [Related]
71. The genetics of generalized vitiligo and associated autoimmune diseases.
Spritz RA
Pigment Cell Res; 2007 Aug; 20(4):271-8. PubMed ID: 17630960
[TBL] [Abstract][Full Text] [Related]
72. Perspectives of New Advances in the Pathogenesis of Vitiligo: From Oxidative Stress to Autoimmunity.
Wang Y; Li S; Li C
Med Sci Monit; 2019 Feb; 25():1017-1023. PubMed ID: 30723188
[TBL] [Abstract][Full Text] [Related]
73. Reactivity to tyrosinase: expression in cancer (melanoma) and autoimmunity (vitiligo).
Merimsky O; Shoenfeld Y; Baharav E; Zigelman R; Fishman P
Hum Antibodies Hybridomas; 1996; 7(4):151-6. PubMed ID: 9140726
[TBL] [Abstract][Full Text] [Related]
74. HLA-A2 restricted, melanocyte-specific CD8(+) T lymphocytes detected in vitiligo patients are related to disease activity and are predominantly directed against MelanA/MART1.
Lang KS; Caroli CC; Muhm A; Wernet D; Moris A; Schittek B; Knauss-Scherwitz E; Stevanovic S; Rammensee HG; Garbe C
J Invest Dermatol; 2001 Jun; 116(6):891-7. PubMed ID: 11407977
[TBL] [Abstract][Full Text] [Related]
75. Occludin Promotes Adhesion of CD8
Zou P; Xiao Y; Deng Q; Shi Y; You R; Pi Z; Liu J; Zhan Y; Zeng Q; Zeng Z; Xiao R
Oxid Med Cell Longev; 2022; 2022():6732972. PubMed ID: 35222802
[TBL] [Abstract][Full Text] [Related]
76. [Melanocyte antibodies in idiopathic vitiligo (author's transl)].
Höfs T; Zugehör M; Morenz J
Dermatol Monatsschr; 1981 Nov; 167(11):685-92. PubMed ID: 7044847
[No Abstract] [Full Text] [Related]
77. The role of IL-17 in vitiligo: A review.
Singh RK; Lee KM; Vujkovic-Cvijin I; Ucmak D; Farahnik B; Abrouk M; Nakamura M; Zhu TH; Bhutani T; Wei M; Liao W
Autoimmun Rev; 2016 Apr; 15(4):397-404. PubMed ID: 26804758
[TBL] [Abstract][Full Text] [Related]
78. Early-onset autoimmune vitiligo associated with an enhancer variant haplotype that upregulates class II HLA expression.
Jin Y; Roberts GHL; Ferrara TM; Ben S; van Geel N; Wolkerstorfer A; Ezzedine K; Siebert J; Neff CP; Palmer BE; Santorico SA; Spritz RA
Nat Commun; 2019 Jan; 10(1):391. PubMed ID: 30674883
[TBL] [Abstract][Full Text] [Related]
79. SIRT3-Dependent Mitochondrial Dynamics Remodeling Contributes to Oxidative Stress-Induced Melanocyte Degeneration in Vitiligo.
Yi X; Guo W; Shi Q; Yang Y; Zhang W; Chen X; Kang P; Chen J; Cui T; Ma J; Wang H; Guo S; Chang Y; Liu L; Jian Z; Wang L; Xiao Q; Li S; Gao T; Li C
Theranostics; 2019; 9(6):1614-1633. PubMed ID: 31037127
[TBL] [Abstract][Full Text] [Related]
80. Mammalian tyrosinase-related protein-1 is recognized by autoantibodies from vitiliginous Smyth chickens. An avian model for human vitiligo.
Austin LM; Boissy RE
Am J Pathol; 1995 Jun; 146(6):1529-41. PubMed ID: 7778691
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
